Cogstate Ltd (ASX:CGS) is preparing to reveal details in connection with its 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Cogstate COGNIGRAMTM System.
The ASX has granted the company a trading halt to prepare.
Cogstate provides enabling technologies for neuropsychological assessments.
The company was recently chosen as a preferred provider to the global healthcare leader, Eli Lilly and Company (NYSE:LLY), to support their Alzheimer’s disease platform with solutions.
The halt will remain in place until the opening of trade on Friday 28th July 2017, or earlier if an announcement is made to the market.